Pharvaris (PHVS) Stock Overview
A late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PHVS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Pharvaris N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.86 |
| 52 Week High | US$26.33 |
| 52 Week Low | US$11.51 |
| Beta | -2.77 |
| 1 Month Change | -8.19% |
| 3 Month Change | -5.96% |
| 1 Year Change | 2.87% |
| 3 Year Change | 323.64% |
| 5 Year Change | n/a |
| Change since IPO | -24.62% |
Recent News & Updates
Recent updates
Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success
Jul 18Here's Why We're Watching Pharvaris' (NASDAQ:PHVS) Cash Burn Situation
Jul 05
We're Hopeful That Pharvaris (NASDAQ:PHVS) Will Use Its Cash Wisely
Mar 17Pharvaris: Despite 30% Decline, Still Fair At Best
Dec 29Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation
Dec 02We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Aug 16Pharvaris: Digging Deep For Sufficient Market Size
Jan 17We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Oct 09Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
May 13Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth
Jan 11We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Sep 26Pharvaris GAAP EPS of -€0.38
Sep 12Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate
Aug 22We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Jun 08Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
Dec 21We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Aug 25Shareholder Returns
| PHVS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.3% | -2.6% | -1.5% |
| 1Y | 2.9% | -7.1% | 14.4% |
Return vs Industry: PHVS exceeded the US Pharmaceuticals industry which returned -7% over the past year.
Return vs Market: PHVS underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| PHVS volatility | |
|---|---|
| PHVS Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PHVS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PHVS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 114 | Berndt Axel Modig | pharvaris.com |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Pharvaris N.V. Fundamentals Summary
| PHVS fundamental statistics | |
|---|---|
| Market cap | US$1.57b |
| Earnings (TTM) | -US$196.74m |
| Revenue (TTM) | n/a |
Is PHVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHVS income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €168.29m |
| Earnings | -€168.29m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PHVS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 16:40 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharvaris N.V. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Steven Seedhouse | Cantor Fitzgerald & Co. |
| Jonathan Wolleben | Citizens JMP Securities, LLC |